To assess metabolic, anthropometric and cardiovascular risk profile of a cohort undergoing stable nevirapine therapy associated with TDF+FTC (TVD), AZT+3TC (CBV) or ABC+3TC (KVX).
Purpose of the study
To assess metabolic, anthropometric and cardiovascular risk profile of a cohort undergoing stable nevirapine therapy associated with TDF+FTC (TVD), AZT+3TC (CBV) or ABC+3TC (KVX).
Methods
Cross-sectional observational study that included all consecutive HIV-infected patients seen at a metabolic clinic undergoing nevirapine therapy for >6 months associated with TVD, CBV or KVX.
Summary of results
244 patients were included. Table 1. Rho of Spearman did not find any correlation between NVP exposure and the surrogate toxicity end-points (all: p = ns).
Conclusion
KVX arm displayed a greater pro-atherogenic risk profile notwithstanding lower BMI in respect to CBV and TVD. This non-randomised cohort cannot discriminate if patients with a higher underlying risk of cardiovascular disease might be initially placed on KVX or if KVX associated with NVP per se, had a poorer metabolic profile compared with the TVD and CBV arms. Careful assessment of metabolic parameters should be evaluated in people undergoing the association KVX+NEV even beyond the initial 6 months of therapy and appropriate lipid-lowering therapy started if needed. 
